RxDoctor Payments Data

John Paulsel, MD

Internal Medicine · Houston, TXNPI 1285611764

Payments from drug & device makers

$1,712in general payments, 2019–2025

Across 85 payments — averaging $20.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$334
  • Novo Nordisk$312
  • Astellas Pharma US Inc$143
  • AstraZeneca$137
  • GSK$118
  • Lilly USA, LLC$118
  • plus $551 from 17 others

What the payments were for

  • Food & beverage$1,61895%
  • Education$945%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,712 in reported general payments places this provider in the 75th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$132,409
Medicare patients
489
Services billed
2,535

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban73$83,573
OzempicSemaglutide66$65,649
EliquisApixaban62$65,269
FarxigaDapagliflozin Propanediol32$34,072
MounjaroTirzepatide23$22,822
JardianceEmpagliflozin18$22,294
LinzessLinaclotide28$18,453
XanaxAlprazolam26$18,355
RexultiBrexpiprazole11$17,650
MyrbetriqMirabegron13$11,072
Testosterone33$10,716
BrilintaTicagrelor15$8,885
SynthroidLevothyroxine Sodium75$7,211
Lantus SolostarInsulin Glargine,hum.Rec.Anlog49$4,695
PaxlovidNirmatrelvir/Ritonavir40$4,396

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$53$83,57373 claims
PfizerEliquis, Paxlovid, Premarin$56$73,911116 claims
Novo NordiskOzempic$312$65,64966 claims
AstraZenecaFarxiga, Brilinta, Symbicort$137$46,35062 claims
AbbVieLinzess, Synthroid$334$25,663103 claims
Lilly USA, LLCMounjaro$118$22,82223 claims
Boehringer IngelheimJardiance$15$22,29418 claims
Astellas Pharma US IncMyrbetriq$143$11,07213 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$17$3,908291 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →